🔊 #D2RProjectSpotlight
Led by Maria Vera Ugalde (McGill), this project explores antisense oligonucleotides, a novel RNA-based approach to help restore cells' natural defense systems and combat neurodegenerative diseases like ALS and Alzheimers.
mcgill.ca/dna-to-rna/f...
Led by Maria Vera Ugalde (McGill), this project explores antisense oligonucleotides, a novel RNA-based approach to help restore cells' natural defense systems and combat neurodegenerative diseases like ALS and Alzheimers.
mcgill.ca/dna-to-rna/f...
September 22, 2026 at 3:25 PM
🔊 #D2RProjectSpotlight
Led by Maria Vera Ugalde (McGill), this project explores antisense oligonucleotides, a novel RNA-based approach to help restore cells' natural defense systems and combat neurodegenerative diseases like ALS and Alzheimers.
mcgill.ca/dna-to-rna/f...
Led by Maria Vera Ugalde (McGill), this project explores antisense oligonucleotides, a novel RNA-based approach to help restore cells' natural defense systems and combat neurodegenerative diseases like ALS and Alzheimers.
mcgill.ca/dna-to-rna/f...
🔊 #D2RProjectSpotlight
Led by Suhad Ali (@rimuhc.bsky.social ) this project is validating a new #RNA-based therapy for triple-negative #breastcancer, an aggressive cancer with limited treatment options.
🔗 mcgill.ca/dna-to-rna/f...
Led by Suhad Ali (@rimuhc.bsky.social ) this project is validating a new #RNA-based therapy for triple-negative #breastcancer, an aggressive cancer with limited treatment options.
🔗 mcgill.ca/dna-to-rna/f...
September 18, 2026 at 1:25 PM
🔊 #D2RProjectSpotlight
Led by Suhad Ali (@rimuhc.bsky.social ) this project is validating a new #RNA-based therapy for triple-negative #breastcancer, an aggressive cancer with limited treatment options.
🔗 mcgill.ca/dna-to-rna/f...
Led by Suhad Ali (@rimuhc.bsky.social ) this project is validating a new #RNA-based therapy for triple-negative #breastcancer, an aggressive cancer with limited treatment options.
🔗 mcgill.ca/dna-to-rna/f...
#D2RProjectSpotlight: RNA therapies for the treatment of a rare neurological disease led by Jo Anne Stratton (@mcgillu) This project aims to understand how RNA-based therapies can be optimized to target Schwann cells, the major cell type affected in Neurofibro
#D2RProjectSpotlight: RNA therapies for the treatment of a rare neurological disease led by Jo Anne Stratton (@mcgillu) This project aims to understand how RNA-based therapies can be optimized to target Schwann cells, the major cell type affected in Neurofibro
News update via NF Bot
bsky.app
February 19, 2026 at 3:39 PM
#D2RProjectSpotlight: RNA therapies for the treatment of a rare neurological disease led by Jo Anne Stratton (@mcgillu) This project aims to understand how RNA-based therapies can be optimized to target Schwann cells, the major cell type affected in Neurofibro
🔊 #D2RProjectSpotlight: mRNA therapy for CLN3 Batten disease led by Professor Carl Ernst (@mcgillu) 🔗 Learn more here: buff.ly/yELbB3f
July 9, 2026 at 2:02 PM
🔊 #D2RProjectSpotlight: mRNA therapy for CLN3 Batten disease led by Professor Carl Ernst (@mcgillu) 🔗 Learn more here: buff.ly/yELbB3f
🔊 #D2RProjectSpotlight: From Bench to Bedside: RNA and AAV Gene Therapies for Diffuse Midline Gliomas led by Professor Nada Jabado (@mcgillu) 🔗 Learn more here: buff.ly/GtdyVpA
July 7, 2026 at 2:07 PM
🔊 #D2RProjectSpotlight: From Bench to Bedside: RNA and AAV Gene Therapies for Diffuse Midline Gliomas led by Professor Nada Jabado (@mcgillu) 🔗 Learn more here: buff.ly/GtdyVpA
🔊 #D2RProjectSpotlight: LNP/mRNA Therapy for Sickle Cell Disease led by Professor Anastasia Nijnik (@mcgillu) 🔗 Learn more here: buff.ly/ezQMPOB
June 30, 2026 at 2:03 PM
🔊 #D2RProjectSpotlight: LNP/mRNA Therapy for Sickle Cell Disease led by Professor Anastasia Nijnik (@mcgillu) 🔗 Learn more here: buff.ly/ezQMPOB
🔊 #D2RProjectSpotlight: From Trial to Gene Therapy: Restoring Differentiation in IDH-Mutant Glioma led by Professor Charles Couturier (@mcgillu) 🔗 Learn more here: buff.ly/OiMiCTi
June 23, 2026 at 2:06 PM
🔊 #D2RProjectSpotlight: From Trial to Gene Therapy: Restoring Differentiation in IDH-Mutant Glioma led by Professor Charles Couturier (@mcgillu) 🔗 Learn more here: buff.ly/OiMiCTi
🧬#D2RProjectSpotlight: Switchable self-amplifying RNA: Safe, Selective, and Programmable Therapeutic Expression led by Prof. Maureen McKeague with collaborator Prof. Anna Blakney 🔗Learn more here: buff.ly/hlfhhvb
May 7, 2026 at 2:30 PM
🧬#D2RProjectSpotlight: Switchable self-amplifying RNA: Safe, Selective, and Programmable Therapeutic Expression led by Prof. Maureen McKeague with collaborator Prof. Anna Blakney 🔗Learn more here: buff.ly/hlfhhvb
🧬#D2RProjectSpotlight: Targeting miRNAs in Embryonal Brain Tumors (@mcgillu Prof. Jacek Majewski) This project will study the molecular effects of this genome rearrangement and explore the use of microRNA inhibitors – sponges – to counteract the oncogenic changes buff.ly/309J3d2
May 5, 2026 at 2:45 PM
🧬#D2RProjectSpotlight: Targeting miRNAs in Embryonal Brain Tumors (@mcgillu Prof. Jacek Majewski) This project will study the molecular effects of this genome rearrangement and explore the use of microRNA inhibitors – sponges – to counteract the oncogenic changes buff.ly/309J3d2
🔊 #D2RProjectSpotlight: D2R - Health Data Science (D2R-HeDS) platform 💡 Scientific Director: Guillaume Bourque (@McGillu) 🔗 Learn more: buff.ly/qDphDDy
#RNA #RNATherapy #RNAResearch
#RNA #RNATherapy #RNAResearch
March 5, 2026 at 3:15 PM
🔊 #D2RProjectSpotlight: D2R - Health Data Science (D2R-HeDS) platform 💡 Scientific Director: Guillaume Bourque (@McGillu) 🔗 Learn more: buff.ly/qDphDDy
#RNA #RNATherapy #RNAResearch
#RNA #RNATherapy #RNAResearch
#D2RProjectSpotlight: End to end sequencing platform for RNA therapeutics quality control (EESPRNATQC) Scientific Director: Ioannis Ragoussis (@mcgillu)🔗 Learn more here: buff.ly/zhzGYc7
March 3, 2026 at 3:45 PM
#D2RProjectSpotlight: End to end sequencing platform for RNA therapeutics quality control (EESPRNATQC) Scientific Director: Ioannis Ragoussis (@mcgillu)🔗 Learn more here: buff.ly/zhzGYc7
🔊 #D2RProjectSpotlight: Centre for Applied Nanomedicine (CAN)💡 Scientific Director: Janusz Rak (RI-MUHC)🧬 Centre for Applied Nanomedicine (CAN) is a place/platform where specialized instruments measure, observe, and characterize myriads of small objects known as nanoparticles 🔗 buff.ly/Hv3NYJV
February 24, 2026 at 3:15 PM
🔊 #D2RProjectSpotlight: Centre for Applied Nanomedicine (CAN)💡 Scientific Director: Janusz Rak (RI-MUHC)🧬 Centre for Applied Nanomedicine (CAN) is a place/platform where specialized instruments measure, observe, and characterize myriads of small objects known as nanoparticles 🔗 buff.ly/Hv3NYJV
#D2RProjectSpotlight: RNA therapies for the treatment of a rare neurological disease led by Jo Anne Stratton (@mcgillu) This project aims to understand how RNA-based therapies can be optimized to target Schwann cells, the major cell type affected in Neurofibromatosis type 2.🔗 buff.ly/QYf2Kfg
February 19, 2026 at 3:15 PM
#D2RProjectSpotlight: RNA therapies for the treatment of a rare neurological disease led by Jo Anne Stratton (@mcgillu) This project aims to understand how RNA-based therapies can be optimized to target Schwann cells, the major cell type affected in Neurofibromatosis type 2.🔗 buff.ly/QYf2Kfg
🔊 #D2RProjectSpotlight: RNA therapeutics to block USP15-driven neuroinflammation in the brain led by Philippe Gros (@mcgillu) this project aims to test the capacity of these USP15 modalities to block neuroinflammation in vivo following delivery to the brain. Learn more: buff.ly/P0QfkgL
February 17, 2026 at 3:05 PM
🔊 #D2RProjectSpotlight: RNA therapeutics to block USP15-driven neuroinflammation in the brain led by Philippe Gros (@mcgillu) this project aims to test the capacity of these USP15 modalities to block neuroinflammation in vivo following delivery to the brain. Learn more: buff.ly/P0QfkgL
🔊 #D2RProjectSpotlight: mRNA Therapy to Prevent Liver Disease Progression in Zellweger Spectrum Disorder led by Nancy Braverman (@McGillu) ZSD is a rare genetic disorder, most patients harbor mutations in PEX1 gene. This project aims to restore PEX1 function. Learn more: buff.ly/3Y93ZQY
February 13, 2026 at 3:00 PM
🔊 #D2RProjectSpotlight: mRNA Therapy to Prevent Liver Disease Progression in Zellweger Spectrum Disorder led by Nancy Braverman (@McGillu) ZSD is a rare genetic disorder, most patients harbor mutations in PEX1 gene. This project aims to restore PEX1 function. Learn more: buff.ly/3Y93ZQY
🔊 #D2RProjectSpotlight: Aptamer-short hairpin RNA conjugation for gene therapy against HIV led by Anne Gatignol (Jewish General Hospital)🧬This research aims to support a more effective procedure in which a person's own cells are modified to make them resistant to HIV.🔗 buff.ly/WudYn1G
February 10, 2026 at 3:04 PM
🔊 #D2RProjectSpotlight: Aptamer-short hairpin RNA conjugation for gene therapy against HIV led by Anne Gatignol (Jewish General Hospital)🧬This research aims to support a more effective procedure in which a person's own cells are modified to make them resistant to HIV.🔗 buff.ly/WudYn1G
🔊 #D2RProjectSpotlight: Lipid Nanoparticles for Nasal mRNA Vaccines💡 Led by Larry Lands (RI-MUHC) 🧬 This project explores delivering RNA vaccines through a nose spray. This nasal method is not only more convenient but could offer better protection for the lungs. 🔗 Learn more: buff.ly/raSze21
February 6, 2026 at 3:02 PM
🔊 #D2RProjectSpotlight: Lipid Nanoparticles for Nasal mRNA Vaccines💡 Led by Larry Lands (RI-MUHC) 🧬 This project explores delivering RNA vaccines through a nose spray. This nasal method is not only more convenient but could offer better protection for the lungs. 🔗 Learn more: buff.ly/raSze21
🔊 #D2RProjectSpotlight: 3’UTR engineering for next-generation T cell mRNA therapeutics led by Thomas Duchaine (@mcgillu) This project aims to improve cancer immunotherapies by designing “smart” RNA switches that control how long therapeutic mRNAs stay active in immune cells. buff.ly/iyMZTzA
February 3, 2026 at 3:30 PM
🔊 #D2RProjectSpotlight: 3’UTR engineering for next-generation T cell mRNA therapeutics led by Thomas Duchaine (@mcgillu) This project aims to improve cancer immunotherapies by designing “smart” RNA switches that control how long therapeutic mRNAs stay active in immune cells. buff.ly/iyMZTzA
🔊 #D2RProjectSpotlight: Development of RNA therapeutics against USP15-dependent neuroinflammation led by Philippe Gros, PhD🧬This project aims to develop inhibitors of USP15 which can dampen neuroinflammation using an RNA therapeutics approach. 🔗 Learn more: buff.ly/o3CRrRl
January 29, 2026 at 3:36 PM
🔊 #D2RProjectSpotlight: Development of RNA therapeutics against USP15-dependent neuroinflammation led by Philippe Gros, PhD🧬This project aims to develop inhibitors of USP15 which can dampen neuroinflammation using an RNA therapeutics approach. 🔗 Learn more: buff.ly/o3CRrRl
🔊 #D2RProjectSpotlight: Targeting MET exon 14 skipping variant in the early metastatic dissemination in lung cancer 🧬 Led by Morag Park (@mcgillgci.bsky.social) this project aims a novel therapy using targeted molecules designed to block this mutation. 🔗 buff.ly/VfPel6h
January 27, 2026 at 3:31 PM
🔊 #D2RProjectSpotlight: Targeting MET exon 14 skipping variant in the early metastatic dissemination in lung cancer 🧬 Led by Morag Park (@mcgillgci.bsky.social) this project aims a novel therapy using targeted molecules designed to block this mutation. 🔗 buff.ly/VfPel6h
#D2RProjectSpotlight: Injectable Hydrogel/mRNA-LNP Platform for In Vivo CAR-T Cell Engineering 🧬Led by Guojun Chen (@McGillu) this project aims to accelerate the development of next-generation immunotherapies buff.ly/Xa2wnaT
January 23, 2026 at 5:01 PM
#D2RProjectSpotlight: Injectable Hydrogel/mRNA-LNP Platform for In Vivo CAR-T Cell Engineering 🧬Led by Guojun Chen (@McGillu) this project aims to accelerate the development of next-generation immunotherapies buff.ly/Xa2wnaT
#D2RProjectSpotlight: Transient CAR-T Cell engineering🧬Led by Taha Azad (@USherbrooke) this project aims to produce safe & effective CAR-Ts, and help accelerate RNA-based cell therapy development buff.ly/Tsz4eBD
January 20, 2026 at 4:03 PM
#D2RProjectSpotlight: Transient CAR-T Cell engineering🧬Led by Taha Azad (@USherbrooke) this project aims to produce safe & effective CAR-Ts, and help accelerate RNA-based cell therapy development buff.ly/Tsz4eBD
#D2RProjectSpotlight: Development of a new blood test to track treatment success and to detect melanoma returning early🧬Led by Ian Watson (@mcgillu) this project aims to improve care for melanoma patients. buff.ly/7cVwU65
January 15, 2026 at 4:01 PM
#D2RProjectSpotlight: Development of a new blood test to track treatment success and to detect melanoma returning early🧬Led by Ian Watson (@mcgillu) this project aims to improve care for melanoma patients. buff.ly/7cVwU65
🔊#D2RProjectSpotlight: From #RNA to personalized #lungdisease treatment
🧬Led by David Langlais (@mcgill.ca), this project aims to identify blood markers for earlier diagnosis and personalized treatment of interstitial lung disease (ILD).
🔗https://shorturl.at/yXxOO
#RNA #RNAtherapies
🧬Led by David Langlais (@mcgill.ca), this project aims to identify blood markers for earlier diagnosis and personalized treatment of interstitial lung disease (ILD).
🔗https://shorturl.at/yXxOO
#RNA #RNAtherapies
January 13, 2026 at 9:38 PM
🔊#D2RProjectSpotlight: From #RNA to personalized #lungdisease treatment
🧬Led by David Langlais (@mcgill.ca), this project aims to identify blood markers for earlier diagnosis and personalized treatment of interstitial lung disease (ILD).
🔗https://shorturl.at/yXxOO
#RNA #RNAtherapies
🧬Led by David Langlais (@mcgill.ca), this project aims to identify blood markers for earlier diagnosis and personalized treatment of interstitial lung disease (ILD).
🔗https://shorturl.at/yXxOO
#RNA #RNAtherapies
#D2RProjectSpotlight
🧬 This project, co-funded by Médicament Québec, RNA Technologies and Therapeutics Inc., AReNA, NovoArc GmbH, and the Victor Phillip Dahdaleh Institute, aims to advance next-generation mRNA vaccines.
🔗 Learn more: buff.ly/NlIVF16
@mcgill-research.bsky.social
🧬 This project, co-funded by Médicament Québec, RNA Technologies and Therapeutics Inc., AReNA, NovoArc GmbH, and the Victor Phillip Dahdaleh Institute, aims to advance next-generation mRNA vaccines.
🔗 Learn more: buff.ly/NlIVF16
@mcgill-research.bsky.social
July 18, 2025 at 1:31 PM
#D2RProjectSpotlight
🧬 This project, co-funded by Médicament Québec, RNA Technologies and Therapeutics Inc., AReNA, NovoArc GmbH, and the Victor Phillip Dahdaleh Institute, aims to advance next-generation mRNA vaccines.
🔗 Learn more: buff.ly/NlIVF16
@mcgill-research.bsky.social
🧬 This project, co-funded by Médicament Québec, RNA Technologies and Therapeutics Inc., AReNA, NovoArc GmbH, and the Victor Phillip Dahdaleh Institute, aims to advance next-generation mRNA vaccines.
🔗 Learn more: buff.ly/NlIVF16
@mcgill-research.bsky.social